Form 4: Regulus Therapeutics Director William H. Rastetter Acquires 30,000 Stock Options

Director William H. Rastetter acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.

Summary

• William H. Rastetter, a director of Regulus Therapeutics Inc., acquired 30,000 stock options on May 16, 2024.
• The options were granted pursuant to the company's Non-Employee Director's Compensation policy.
• The exercise price of the options is $2.01.
• The options vest ratably over twelve months and will be fully vested one year after the grant date or on the date of the company's next annual stockholder meeting, whichever occurs first, subject to continuous service.
• The options expire on May 15, 2034.
• Rastetter also indirectly owns 30,000 derivative securities through the Rastetter Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a grant of stock options to a director, which is a common practice for compensating board members.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates